Menu Back toOS03: Expedited Approval Systems to Accelerate Patient Access to Innovative Drugs in Japan and the US

18th DIA Japan Annual Meeting 2021

All prices are exclusive of 10% Japanese consumption tax

OS03: Expedited Approval Systems to Accelerate Patient Access to Innovative Drugs in Japan and the US

Session Chair(s)

Kanji  Hirai, RPh

Kanji Hirai, RPh

  • Director, Regulatory Policy & Intelligence, Regulatory Affair Area, Japan Dvlpmt
  • MSD K.K., Japan

Speaker(s)

Geet  Mankad

Geet Mankad

  • Director, Global Regulatory Affairs
  • MSD K.K., Japan
Ryo  Muto

Ryo Muto

  • Associate Director, Regulatory Affairs Oncology
  • Daiichi Sankyo Co., Ltd., Japan
Yoko  Aoi, PharmD

Yoko Aoi, PharmD

  • Principal Reviewer, Office of New Drug V
  • Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Contact us